Cardiol Therapeutics Inc.
CRDL.TOTSXHealthcare● Active
$1.51
$-0.06(-3.82%)
Market Cap$168926720
P/E Ratio—
52W High$2.33
52W Low$1.225
Cardiol Therapeutics Inc. (CRDL.TO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CRDL.TO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.10
Est. -$0.09 · -11.1%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▼ Miss EPS
CRDL.TO reports quarterly as a TSX-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 17, 2026 | -$0.10 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 14, 2026 | -$0.09 | -$0.10 | -11.1% | — | — | — |
| ▲ Q2 FY2026 | Apr 1, 2026 | -$0.11 | -$0.07 | +38.8% | — | — | — |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$0.11 | -$0.12 | -6.9% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.13 | -$0.10 | +22.3% | — | — | — |
| ▲ Q2 FY2025 | May 12, 2025 | -$0.14 | -$0.10 | +28.6% | — | — | — |
| ▲ Q4 FY2024 | Dec 31, 2024 | -$0.13 | -$0.10 | +21.1% | — | — | — |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.12 | -$0.18 | -50.0% | — | — | — |
Q3 FY2026
Aug 17, 2026
EPS Actual
—
EPS Est.
-$0.10
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Miss
EPS Actual
-$0.10
EPS Est.
-$0.09
EPS Surpr.
-11.1%
Revenue
—
Q2 FY2026
Apr 1, 2026Beat
EPS Actual
-$0.07
EPS Est.
-$0.11
EPS Surpr.
+38.8%
Revenue
—
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$0.12
EPS Est.
-$0.11
EPS Surpr.
-6.9%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.10
EPS Est.
-$0.13
EPS Surpr.
+22.3%
Revenue
—
Q2 FY2025
May 12, 2025Beat
EPS Actual
-$0.10
EPS Est.
-$0.14
EPS Surpr.
+28.6%
Revenue
—
Q4 FY2024
Dec 31, 2024Beat
EPS Actual
-$0.10
EPS Est.
-$0.13
EPS Surpr.
+21.1%
Revenue
—
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$0.18
EPS Est.
-$0.12
EPS Surpr.
-50.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q3 FY2026 | $-0.14 | $-0.10 | $-0.08 | 3 |
| Q2 FY2026 | $-0.12 | $-0.10 | $-0.08 | 3 |
| Q1 FY2026 | $-0.10 | $-0.09 | $-0.08 | 3 |
| Q4 FY2025 | $-0.12 | $-0.11 | $-0.10 | 2 |
| Q3 FY2025 | $-0.10 | $-0.10 | $-0.09 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 14, 2026 | -11.1% | $1.87 | $1.87 | +0.00% |
| ▲ Q2 FY2026 | Apr 1, 2026 | +38.8% | $1.89 | $1.95 | +3.17% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -6.9% | $1.46 | $1.47 | +0.68% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +22.3% | $1.53 | $1.85 | +20.92% |
| ▲ Q2 FY2025 | May 12, 2025 | +28.6% | $1.60 | $1.59 | -0.63% |
| ▲ Q4 FY2024 | Dec 31, 2024 | +21.1% | $1.84 | $1.85 | +0.54% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -50.0% | $2.66 | $2.62 | -1.50% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +23.1% | $2.77 | $2.77 | +0.00% |
Q2 FY2026+0.00%
Report Date
May 14, 2026
EPS Beat/Miss
-11.1%
Price Before
$1.87
Price After
$1.87
Q2 FY2026+3.17%
Report Date
Apr 1, 2026
EPS Beat/Miss
+38.8%
Price Before
$1.89
Price After
$1.95
Q4 FY2025+0.68%
Report Date
Nov 13, 2025
EPS Beat/Miss
-6.9%
Price Before
$1.46
Price After
$1.47
Q3 FY2025+20.92%
Report Date
Aug 14, 2025
EPS Beat/Miss
+22.3%
Price Before
$1.53
Price After
$1.85
Q2 FY2025-0.63%
Report Date
May 12, 2025
EPS Beat/Miss
+28.6%
Price Before
$1.60
Price After
$1.59
Q4 FY2024+0.54%
Report Date
Dec 31, 2024
EPS Beat/Miss
+21.1%
Price Before
$1.84
Price After
$1.85
Q4 FY2024-1.50%
Report Date
Nov 14, 2024
EPS Beat/Miss
-50.0%
Price Before
$2.66
Price After
$2.62
Q3 FY2024+0.00%
Report Date
Aug 12, 2024
EPS Beat/Miss
+23.1%
Price Before
$2.77
Price After
$2.77
Avg Beat Reaction+4.80%
Avg Miss Reaction-0.27%
Beat Rate5 / 8 quarters
Largest Move+20.92% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CRDL.TO ends December
Cardiol Therapeutics Inc. (CRDL.TO) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.10 — missing the analyst consensus of $-0.09 by -11.1%. The next CRDL.TO earnings date is expected around September 1, 2026.
Each quarter, investors track CRDL.TO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CRDL.TO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CRDL.TO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CRDL.TO earnings · 5 questionsCardiol Therapeutics Inc.'s next earnings report is expected around September 1, 2026. CRDL.TO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CRDL.TO historically reports after market close (AMC).
CRDL.TO earnings datewhen is CRDL.TO earningsCRDL.TO next earnings datewhen does CRDL.TO report earningsCRDL.TO earnings calendar
▸ Source: FMP · Cardiol Therapeutics Inc. SEC filings · US GAAP · Cardiol Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026